Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On January 16, 2023, Ernest De Paolantonio, the Chief Financial Officer of
Journey Medical Corporation (the "Company") provided notice to the Company of
his resignation, effective January 27, 2023. Mr. De Paolantonio will consult
with and advise the Company until March 31, 2023.
In connection with such resignation, Joseph Benesch, age 56, the Company's
Corporate Controller, was appointed as the Company's interim Chief Financial
Officer, effective January 27, 2023. Mr. Benesch's compensation has not changed
as a result of this appointment. Any changes to Mr. Benesch's compensation
package, if any, will be determined by the Company's Board of Directors upon
recommendation of its Compensation Committee.
Mr. Benesch was hired as the Company's Corporate Controller in November 2021. He
previously served as the Principal Accounting Officer, Vice President and
Corporate Controller of Teligent Pharma Inc., a specialty generic pharmaceutical
company, and Corporate Controller of Torrent Pharmaceuticals Ltd., a U.S.
subsidiary of the Torrent Group, a multinational pharmaceutical company. Before
joining Torrent Pharmaceuticals Ltd., he held senior financial management
positions from corporate controller to Vice President of Finance at Savient
Pharmaceuticals, Adare Pharmaceuticals, Inc. and Edenbridge Pharmaceuticals. He
began his career in the public accounting sector at Baker Tilly Virchow Krause,
LLP, and Ernst and Young Global Limited, working with a diverse client base. He
is a Certified Public Accountant with an active license. Mr. Benesch is a
graduate of Wilkes University where he earned a BA in accounting.
No family relationships exist between Mr. Benesch and any of the Company's
directors or executive officers. There are no arrangements or understandings
between Mr. Benesch and any other person pursuant to which Mr. Benesch was
selected as the Company's interim Chief Financial Officer, nor are there any
transactions to which the Company is or was a participant and in which Mr.
Benesch has a material interest subject to disclosure under
Item 404(a) of Regulation S-K.
A press release related to Mr. De Paolantonio's departure and Mr. Benesch's
appointment is attached as Exhibit 99.1 to this report and is incorporated by
reference to this Item 5.02.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are furnished herewith:
Exhibit
Number Description
99.1 Press Release, dated January 20, 2023.
Cover Page Interactive Data File, formatted in Inline Extensible
104 Business Reporting Language (iXBRL).
© Edgar Online, source Glimpses